Cytos’ CYT003 Fails to Achieve Clinical Trial Endpoint

Cytos Biotechnology yesterday announced that their Phase IIb clinical study of CYT003 failed to meet its primary or secondary endpoints. The clinical trial tested patients with moderate to severe allergic asthma,  and showed that the immune modulator did not achieve a statistically significant reduction of the Asthma Control Questionnaire (ACQ) score at week 12 in

Continue Reading

Positive Results for Pfizer’s Lung Cancer Therapy, Xalkori

click Xalkori” src=”http://i61.tinypic.com/kng1x.jpg” width=”204″ height=”126″ />Pfizer have announced positive late-stage clinical data from a phase III trial of Xalkori, in comparison to chemotherapy. Pfizer revealed that the clinical study met the primary objective of significantly prolonging progression-free survival in previously-untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC), when compared

Continue Reading

Eli Lilly Reveal Positive Clinical Trial Results for Dulaglutide

Eli Lilly has announced the results of their head-to-head clinical study which demonstrates that their investigational GLP-1 glucagon-like peptide 1 receptor agonist, dulaglutide,  is just as effective as Novo Nordisk’s Victoza, the market-leader in the area. The pharmaceutical company revealed the positive top-line results of the sixth clinical trial in their AWARD programme, whereby once-weekly

Continue Reading

Positive Clinical Study Results for Pfizer’s Chantix

Pfizer announced yesterday that Chantix/Champix (varenicline) has been shown to help smokers unable to quit ‘cold turkey’ kick their habit by slowly reducing the amount of cigarettes they smoke. The initial clinical study to assess the drug demonstrated that Chantix/Champix helped improve abstinence rates, in people wanting to reduce smoking prior to quitting.

Continue Reading

Health Economics Increasingly Inputs into Clinical Development

Payer demand for value indicators that can guide compensation conclusions are prompting top pharmaceutical companies to increasingly request input into clinical development from their health economics department, according to a new study. While clinical data is fundamental in driving reimbursement decisions, companies that only evaluate finished clinical trial data to determine a product’s economic benefit

Continue Reading

J&J and GlaxoSmithKline’s Sirukumab Phase III Trials Begin

GlaxoSmithKline and Johnson & Johnson (J&J) announced yesterday that they have started Phase III clinical trials of their investigational rheumatoid arthritis (RA) treatment, sirukumab. Johnson & Johnson’s Janssen Biologics unit in Ireland and GlaxoSmithKline have begun a Phase III development programme for sirukumab (otherwise known as CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody.  The

Continue Reading